Document is current

Article History

Received: 16 October 2025

Accepted: 11 January 2026

First Online: 19 February 2026

Conflict of interest

: The expert meeting was organized and financially supported by ALK-Abelló Arzneimittel GmbH. All authors, except S. Gernert and S. Schnadt, received compensation for their time and travel expenses. R. Treudler reports personal fees from ALK-Abelló for participation in this expert meeting, as well as honoraria from Viatris/Mylan, Sanofi, Pfizer, AbbVie, Amgen, Almirall, Novartis, Galderma, Leo Pharma, and ALK-Abelló, all outside the submitted work. K. Beyer reports personal fees from ALK-Abelló for participation in this expert meeting. K. Blümchen reports personal fees from ALK-Abelló for participation in this expert meeting. S. Gernert reports personal fees from Allergopharma and HAL, as well as speaking fees from GPAU e. V., WAPPA e. V., AGPAS e. V., and DAAB e. V. M. Gerstlauer reports personal fees from ALK-Abelló for participation in this expert meeting. E. Hamelmann reports personal fees from ALK-Abelló for participation in this expert meeting. T. Jakob reports personal fees from ALK-Abelló for participation in this expert meeting and grants and personal fees from Novartis GmbH, Bencard, Galderma, Sanofi, Thermo Fisher, and Leo, all outside the submitted work. T. Jakob is editor of the Allergo Journal and Allergo Journal International . L. Klimek reports personal fees from ALK-Abelló for participation in this expert meeting. L. Klimek is editor of the Allergo Journal and Allergo Journal International . O. Pfaar reports receiving a service fee from ALK-Abelló Arzneimittel GmbH, Germany, for participating in this expert meeting. He also reports receiving research funding and/or service fees and/or travel support from AEDA, Alfried Krupp Krankenhaus, ALK-Abelló, Allergopharma, Almirall, Altamira Therapeutics, ASIT Biotech, AstraZeneca, Bencard Allergie GmbH/Allergy Therapeutics, Blueprint, Breazy Health, Cliantha, Deutsche Allergie Liga e. V., Deutsche Forschungsgemeinschaft, Dustri-Verlag, ECM Expo & Conference Management GmbH, Forum für Medizinische Fortbildung, Georg-Thieme-Verlag, GlaxoSmithKline (GSK), HAL Allergy Holding B.V./HAL Allergie GmbH, Inmunotek, Ingress Health, Institut für Disease Management, IQVIA Commercial, Japanese Society of Allergology, Königlich Dänisches Generalkonsulat, Laboratorios LETI/LETI Pharma, Lilly, Lofarma, Medizinische Hochschule Hannover, med update europe GmbH, Meinhardt Congress GmbH, Novartis, Paul-Ehrlich-Institut, Paul-Martini-Stiftung, PneumoLive, Pohl-Boskamp, Procter & Gamble, Red Maple Trials Inc., Regeneron, RG Aerztefortbildung, ROXALL Medizin, Sanofi Aventis, Sanofi Genzyme, Springer Publisher, Stallergenes Greer, streamedup! GmbH, Technical University Dresden, John Wiley & Sons publishers, Wort & Bild Verlag, and Verlag ME, all outside the submitted work. Pfaar is the Vice President of the European Academy of Allergy and Clinical Immunology (EAACI), a member of the Board/ExCom of EAACI, and a member of the extended board of the German Society for Allergology and Clinical Immunology (DGAKI). He serves as a coordinator, primary author, or co-author of various position papers and guidelines in the fields of rhinology, allergology, and allergen immunotherapy. He is Editor-in-Chief of the journal Clinical Translational Allergy (CTA, Wiley) and Associate Editor of the journal Allergy (Wiley). F. Ruëff reports personal fees from ALK-Abelló for participation in this expert meeting. S. Schnadt reports no conflicts of interest. M. Schönherr reports personal fees from ALK-Abelló for participation in this expert meeting. S. Seurig reports personal fees from ALK-Abelló Arzneimittel GmbH for participation in this expert meeting and payments or honoraria for lectures, presentations, manuscript writing, or educational events from companies including AstraZeneca GmbH and Allergopharma GmbH & Co. KG. C. Vogelberg reports personal fees from ALK-Abelló for participation in this expert meeting, as well as honoraria for lectures and consultation from various organizations, including ALK-Abelló, AstraZeneca, Sanofi, and Allergy Therapeutics. D. Wieczorek reports personal fees from ALK-Abelló for participation in this expert meeting and honoraria for lectures, presentations, and training events from ALK-Abelló, Novartis, and DGAKI, as well as compensation for participating in meetings organized by ALK-Abelló and DGAKI. M. Worm reports personal fees for participation in this expert meeting and honoraria from AbbVie, Aimmune, ALK-Abelló, Allergopharma, AstraZeneca, Bayer, Galderma, GlaxoSmithKline, Novartis, Sanofi, and many other organizations, all outside the submitted work. E. Wüstenberg serves as Vice President Medical Affairs Europe at ALK-Abelló and holds shares in ALK-Abelló.